GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BGLAF) » Definitions » Total Assets

BioGaia AB (BioGaia AB) Total Assets : $238.2 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Total Assets?

BioGaia AB's Total Assets for the quarter that ended in Mar. 2024 was $238.2 Mil.

Warning Sign:

If a company builds assets at 17.4% a year, faster than its revenue growth rate of 7.7% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, BioGaia AB's average Total Assets Growth Rate was 19.60% per year. During the past 3 years, the average Total Assets Growth Rate was 21.00% per year. During the past 5 years, the average Total Assets Growth Rate was 17.40% per year. During the past 10 years, the average Total Assets Growth Rate was 17.80% per year.

During the past 13 years, BioGaia AB's highest 3-Year average Total Assets Growth Rate was 35.30%. The lowest was -1.90%. And the median was 18.20%.

Total Assets is connected with ROA %. BioGaia AB's annualized ROA % for the quarter that ended in Mar. 2024 was 20.11%. Total Assets is also linked to Revenue through Asset Turnover. BioGaia AB's Asset Turnover for the quarter that ended in Mar. 2024 was 0.15.

BioGaia AB Total Assets Historical Data

The historical data trend for BioGaia AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Total Assets Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.60 228.78 234.12 213.33 227.46

BioGaia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.83 200.30 207.88 227.46 238.20

BioGaia AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BioGaia AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=197.936+29.524
=227.5

BioGaia AB's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=208.241+29.96
=238.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB  (OTCPK:BGLAF) Total Assets Explanation

Total Assets is connected with ROA %.

BioGaia AB's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=46.812/( (227.46+238.201)/ 2 )
=46.812/232.8305
=20.11 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BioGaia AB's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=35.519/( (227.46+238.201)/ 2 )
=35.519/232.8305
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BioGaia AB Total Assets Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGaia AB (BioGaia AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BGLAF) » Definitions » Total Assets
Comparable Companies
OSTO:SECARE OSTO:PROB OSTO:CRNO B XSAT:EQL OSTO:MOB OSTO:ORX OSTO:ENZY OSTO:VIVE XSAT:DICOT OSTO:ERMA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
BIOGY:USA BIOG B:Sweden 0GTN:UK BGLA:Germany
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
Website
https://www.biogaia.se
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.